Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 2001, p. 802-805, Vol. 8, No. 4
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.4.802-805.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Antibody Maturation in Trypanosoma
cruzi-Infected Rats
Iván S.
Marcipar,1,*
Marikena G.
Risso,1
Ariel M.
Silber,1
Silvia
Revelli,2 and
Alberto
J.
Marcipar1
INTEBIO, Facultad de Bioquímica y Cs.
Biológicas, Universidad Nacional del Litoral, 3000 Santa
Fe,1 and Instituto de
Inmunología, Facultad de Medicina, Universidad Nacional de
Rosario, 2000 Rosario,2 Argentina
Received 18 January 2001/Returned for modification 26 February
2001/Accepted 9 May 2001
 |
ABSTRACT |
The study of antibody avidity changes during infection has improved
the understanding of the pathologic processes involved in several
infectious diseases. In some infections, like toxoplasmosis, this
information is being used for diagnostic purposes. Results of the
evolution of antibody avidity for different specific antigens in
Trypanosome cruzi-infected rats are presented. A Western
blotting technique, combined with avidity analysis to identify antigens that elicit high-avidity antibodies, is suggested. In this system, antibodies showed high avidity values only during the chronic phase of
infection and only in relation to antibodies against 21-, 33-, 41-, 42-, 56-, 58-, 66-, and 72-kDa antigens. Finally, a 97-kDa T. cruzi antigen, which was recognized by high-avidity antibodies
and occurred in noninfected rats, was identified. These results allow
us to evaluate the different antigens in chagasic infection. Our
results show that with the correct choice of antigen it is possible to
detect differences in maturation of antibodies and to discriminate, in
an experimental model, between recent (acute) and chronic infections.
 |
INTRODUCTION |
Chagas' disease is caused by the
hematic protozoan Trypanosoma cruzi. The infectious process
in humans is characterized by an initial phase with large quantities of
parasites in peripheral blood. The presence of the parasite in the
bloodstream is partially controlled by the immune response. In most
cases, the infection evolves toward a chronic phase characterized by
high titers of immunoglobulin G (IgG) antibodies, by low and
intermittent parasitemia, and very frequently by the absence of symptoms.
As in other parasitic and infectious diseases, the monitoring of
antibody responses and antigens involved in different stages of the
infection may give information for the comprehension of the mechanisms
of immune system control over the parasite (1, 14, 17, 20,
24). In different infectious processes the maturation of
antibodies, measured in terms of avidity, has been determined in order
to find a correlation with the evolution of the infection (7, 8,
10, 18, 25).
An optimization process of the antibody binding properties has been
described in long-term infection (19): somatic
hypermutation of sequences encoding the variable region of light and
heavy chains of immunoglobulins occurs, and B lymphocytes producing
better quality antibodies, mainly in terms of avidity, are then
selected. During this stage, some serum immunoglobulins evolve from low to high avidity. On the basis of this mechanism, methods have been
developed to age a variety of infective diseases by using a simple
method based on the selective unbinding of antibodies with chaotropic
agents and the assessment of the evolution of their functional avidity
(4, 9, 21). Another type of information that it is
possible to obtain from the determination of the avidity index is the
discrimination between autoantibodies and cross-reacting antibodies
generated by an infectious process (17).
In this work, the evolution of the antibody response to different
T. cruzi antigens in a well characterized Chagas' infection experimental model (6, 22) was studied. Antigens that
elicit antibodies with different avidity patterns were identified.
 |
MATERIALS AND METHODS |
Experimental infection of rats.
Sera used in the
present study were obtained from I strain rats experimentally infected
on day 21 after birth. This strain is derived from a cross between
Rattus novergicus and eIIM rats. Rats were infected with
T. cruzi trypomastigotes (Tulahuen strain) by the
subcutaneous route. Infective parasites were maintained by serial
passage in CBi mice. Different groups of six rats each were sacrificed
7, 15, 30, and 60 days after inoculation. Sera were obtained from blood
taken by cardiac puncture. Control sera were obtained the same way from
noninfected rats.
Determination of blood parasitemia.
Bloodstream forms of
T. cruzi were assessed under standardized conditions by
direct microscopic observation of 5 µl of heparinized blood at 7, 15, 30, and 60 days. Data were expressed as the mean ± the standard
deviation of parasites per 100 fields for each group.
Parasite antigens.
Epimastigotes of the Tulahuen strain were
grown in liver infusion tryptose medium (3). Parasites
were washed with phosphate-buffered saline (PBS), resuspended in
distilled water with 1 mM phenylmethylsulfonyl fluoride (Sigma), and
clarified by centrifugation at 10,000 × g at 4°C for
30 min after two freeze-thaw cycles. The supernatant, containing a
complex mixture of T. cruzi antigens, was used in enzyme-lynked immunosorbent assays (ELISAs) and Western blotting (WB)
assays as described below.
Determination of kinetics of anti-T. cruzi antibody
levels in rat serum by ELISA.
Serum pools from the different
groups of infected and noninfected animals were used to study the
levels of total antibodies and IgG antibodies against T. cruzi antigens. Antigens described above were diluted to 10 µg/ml with pH 9.6 carbonate buffer; microtiter plates (Costar,
Cambridge, Mass.) were coated with 0.1 ml of diluted antigen per well
and incubated overnight at 4°C. Plates were washed with PBS, blocked
with 0.2 ml of 5% nonfat milk (Molico-Nestle) in PBS for 1 h at
37°C, and washed three times with PBS-0.01% Tween 20 (Sigma, St.
Louis, Mo.). Each pool, diluted 1:100, was then incubated for 1 h
at 37°C in six parallel wells. After washing with PBS-0.01% Tween,
half of the wells were incubated with anti-rat IgG- and
IgM-peroxidase conjugates (Jackson Inc., West Grove, Pa.) and the
remaining ones were incubated with anti-rat IgG-peroxidase conjugate
(Jackson Inc.). Wells were incubated for 1 h at 37°C, washed
three times with PBS-0.01% Tween, and developed with hydrogen peroxide-3,3',5,5'-tetramethylbenzidine (RDI, Flanders, N.J.). The
reaction was blocked after 15 min with 2 N
H2SO4, and optical density at 450 nm
(OD450) was read (MAXline microplate reader; Molecular
Devices, Sunnyvale, Calif.).
Avidity ELISA.
Plates were coated as described above and
incubated for 30 min with 6 M urea (ICN, Costa Mesa, Calif.) in PBS.
Microplates were then washed with PBS and blocked with 0.2 ml of
PBS-5% nonfat milk for 1 h at 37°C. Each serum sample was
diluted 1:100 with 1% nonfat milk in PBS and incubated in six parallel
wells for 60 min. After incubation, microplates were thoroughly washed
with PBS-0.01% Tween 20. The three wells containing each serum sample were treated with PBS-6 M urea (ICN) for 30 min. The three remaining wells for each serum sample were incubated with PBS. After washing, samples were incubated with specific anti-rat IgG antibody-peroxidase conjugate (Jackson) for 60 min and then washed and developed with hydrogen peroxide-3,3',5,5'-tetramethylbenzidine (RDI). The
reaction was blocked after 15 min with 2 N
H2SO4 and read at 450 nm as described earlier.
The avidity index (AI) was defined as mean OD450 of
urea-treated wells/mean OD450 of urea-untreated wells × 100. AI was calculated in triplicate for the first, second, and
third pairs of treated and untreated wells, and mean values and
standard deviations were calculated.
Avidity WB.
Parasite extracts were separated by sodium
dodecyl sulfate-12% polyacrylamide gel electrophoresis as previously
described (12) and then electroblotted to nitrocellulose
membranes. Strips were washed in PBS for 5 min and then incubated with
PBS-6 M urea for 30 min. The membranes were blocked for 1 h at
room temperature with PBS-5% nonfat milk. Membranes were washed with
PBS and incubated with primary antibody (1:50 rat serum dilution in
PBS-1% nonfat milk, two strips each) at room temperature for 60 min.
Membranes were washed three times for 5 min and then one strip was
incubated for 30 min with PBS-6 M urea at room temperature for 30 min
while the other one was incubated with PBS. All the strips were
submitted to three washing cycles with PBS, and then membranes were
incubated with anti-rat IgG antibody-peroxidase conjugate (Jackson
Inc.). After a new washing step (three times), the strips were treated with 0.4% hydrogen peroxide 3,3'-diaminobenzidine tetrahydrochloride (Sigma Chemical Co.) in PBS.
Statistical analysis.
Statistical differences among groups
for avidity indexes between 15, 30, and 60 days were calculated by
using a one-way analysis of variance.
 |
RESULTS |
As mentioned earlier, a well-characterized experimental
model using 21-day-old experimentally infected rats was chosen
(6, 22). The acute phase of the infection is defined as
the period in which rats present high parasitemia. When parasites can
no longer be detected in the bloodstream, the chronic phase begins. The
parasitemia was analyzed during infection (Fig.
1A). As described in previous reports,
the peak was reached on day 7 postinfection (p.i.) and parasites could
not be detected after day 30 (22).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
Evolution of parasitemia and antibody levels in rat
sera. (A) Clearance of blood-circulating parasites in T. cruzi-infected rats. The bars represent means ± standard
deviations of parasites in 100 fields. (B) Kinetics after T. cruzi infection in control and infected rats on days 7, 15, 30, and 60 p.i. , total antibody after inoculation in controls
rats; , IgG-specific antibody after inoculation in control rats;
, total antibody after inoculation in infected rats; ,
IgG-specific antibody after inoculation in infected rats. Points are
averages of triplicate experiments. Standard deviations are less than
10%. All groups were assayed on the same ELISA plate. OD was obtained
for each group with both conjugates in order to assess the serological
response from the onset of the infection.
|
|
Serologic status during the acute and chronic phases of infection was
determined by follow-up of specific gamma globulin and IgG isotypes by
using ELISA (Fig. 1B). Levels of IgG isotype antibodies increased and
showed a small peak on day 15 p.i. Specific gamma globulin levels
decreased from day 7 to day 30 p.i. when the lowest levels of both
IgG plus IgM and IgG isotype were observed. Then both values increased,
mainly due to IgG isotype, reaching the maximum on day 60 p.i.
Avidity ELISAs using sera taken from infected animals were
performed. The corresponding indices and evolution of antibody avidity against total antigens were determined (Fig.
2). Specific IgG isotype levels on day
7 p.i. were not detectable by ELISA, so in this case the avidity
index could not be calculated. From 15 to 30 days p.i., no
modifications in the avidity indices were shown by ELISA. However, the
avidity index of antibodies from infected animals increased 23.3% ± 2.7% on day 60 p.i.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
Evolution of the avidity index in sera pools from
infected rats on days 15, 30, and 60 p.i. Differences were
statistically significant at day 60 p.i. (P < 0.0002).
|
|
WB and avidity WB assays were performed in order to recognize the
antigens involved in avidity maturation (Fig.
3). The avidity Western blot patterns are
summarized in Table 1. High-avidity antibodies recognized at day 7 p.i. included a 97-kDa band in both
infected and control rats. Low-avidity antibodies that eluted with the
urea solution were found against seven major bands (41, 42, 56, 58, 66, 72, and 97 kDa) on day 15 p.i. The situation was quite similar on
day 30 p.i.: low-avidity antibodies against five major bands (56, 58, 66, 70, and 72 kDa) were found and completely eluted with urea-PBS,
but antigens of 41, 42, and 97 kDa were not recognized. On the other
hand, a new band of low-avidity antibodies against a 71-kDa antigen
appeared and evolved to high-avidity antibodies on day 60 p.i.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 3.
(A) WB of sera from different groups of infected rats;
non-urea-eluted antibodies (a) and urea-eluted antibodies (b) were
measured on days 7, 15, 30, and 60 p.i. (B) WB of control sera on
days 7, 15, 30, and 60 p.i., with non-urea-eluted antibodies (a)
and urea-eluted antibodies (b). Strips were incubated with
peroxidase-conjugated anti-rat IgG. Apparent molecular mass is shown on
the left.
|
|
A clear differentiation was observed between antibodies evolving to
high avidity on day 60 p.i. (those that recognized bands of 21, 33, 41, 42, 56, 58, 66, and 72 kDa) and those not evolving to high
avidity (the ones recognizing bands of 16, 18, 24, 36, 37, 47, 48, 52, 71, 89, 91, 95, and 97 kDa). A 97-kDa band with high avidity was
observed in all newborns at 7 days p.i. in controls as well as in
inoculated rats; this band disappears in inoculated rats at 15 days
p.i. and is observed again with low avidity at 30 and 60 days p.i.
 |
DISCUSSION |
As previously reviewed, an avidity ELISA using complex
antigens enables us to measure antibody avidity and determine primary infection in several diseases. Many diagnostic studies for other infections have been performed this way (8, 13, 20). The authors observed a high correlation between acute infection and low
avidity indices calculated by using the avidity ELISA technique. It has
been suggested that high avidity indices are chronic infection markers.
However, low avidity indices cannot always be considered acute
infection markers, since it was found that some individuals do not
develop high-avidity antibodies during the chronic phase of
toxoplasmosis (5, 20). Recently, an avidity determination by WB has been suggested for discriminating antigens related to high-avidity antibodies from those related to low-avidity antibodies in
the acute phase of infection (15). In experimental rat
infection by T. cruzi, both avidity ELISA and avidity WB
showed that high-avidity antibodies appeared on day 60 p.i.
Although avidity WB and avidity ELISA are techniques based on different
principles, with differences in terms of sensitivity and the way in
which antigens are presented to antibodies, results with the two
techniques were qualitatively comparable. In fact, both methods showed
a qualitative difference in terms of avidity on day 60 p.i.,
compared to avidity on days 15 and 30 p.i. Parasitemia and
antibody curves indicated that, at this point, rat infection had
reached the chronic stage.
Avidity WB proved to be a valuable technique to identify antigens bound
to high- or low-avidity antibodies. It reveals the avidity evolution,
which is modulated in different ways by different antigens. This
suggests that antibody avidity evolution is induced by each antigen in
an independent manner, as has already been reported for rubella
(16), varicella-zoster virus (11), and human
immunodeficiency virus (25) infections. These findings showed that different viral proteins had different maturation patterns
during infection. It was also observed that avidity patterns appeared
to be independent from antibody concentration, since the remaining
signal after chaotropic elution was not related to the initial
intensity of the bands. The most intense 70-kDa band observed on day
60 p.i. completely disappeared when treated with urea, while the
light 21- and 33-kDa bands recognized by the same antibody pool did not
elute when treated with urea. These results suggest, on one hand, that
this technique is detecting antibody avidity and not antibody
concentration. On the other hand, the results confirm previous
findings, showing that there is no relationship between antibody
concentration and avidity (24).
The quality of the antibody response was consequently heterogeneous,
varying in time and with the antigen used. Antibodies against some
specific antigens (bands of 41, 42, 56, 58, and 66 kDa) were found to
increase their avidity. At the same time, specific antibodies for other
antigens, in particular 70-kDa bands, did not increase their avidity.
Avidity WB results were intriguing: high-avidity antibodies recognizing
the 97-kDa band were universally present in offspring from both control
and infected rats. It would be of interest to study the possible
maternal origin of these high-avidity antibodies found at birth. The
avidity of these antibodies decreased, showing a minimum at day 30 after birth, and then increased in noninfected control rats, perhaps
due to the replacement of maternal antibodies. In infected rats, these
antibodies did not recover their high avidity during the follow-up
period of 60 days. The presence of this antibody population in this rat
strain, which is capable of controlling the chagasic infection,
suggests the possibility of a protective role for these antibodies.
Functional avidity of specific antibodies is a parameter that has been
proposed to correlate with their protective activity. In this
direction, previous work correlated antibody avidity with effector
activity in terms of neutralizing capacity (2) or complement-mediated cytotoxicity (23). This work shows
that there is a differential maturation of antibodies against different antigens associated with the immune response to T. cruzi.
Our results show that, in an experimental model and with a correct
choice of antigen, it is possible to discriminate between recent
(acute) and chronic infections. As a second step of this work, we are
cloning these antigens and studying their application for determining
avidities and their correlations with the clinical manifestations of
the disease in human patients.
 |
ACKNOWLEDGMENTS |
This work was supported by Fundación de Investigaciones
Biomédicas (grant number FIB 005/99). I.S.M. is a fellow of the Secretaria de Cultura de la Provincia de Santa Fe. M.G.R. is a fellow
of the Universidad Nacional del Litoral. A.M.S. is a fellow of the
Consejo Nacional de Investigaciones Científicas y
Técnicas.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: INTEBIO, Ciudad
Universitaria, Paraje El Pozo C. C. 530 CP, 3000 Santa Fe,
Argentina. Phone: (54) (42) 4575216, ext. 125. Fax: (54) (42) 4575219. E-mail: marcipar{at}fbcb.unl.edu.ar.
 |
REFERENCES |
| 1.
|
Andersson, A.,
V. Vetter,
L. Kreuzer, and G. Bauer.
1994.
Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr serology.
J. Med. Virol.
43:238-244[Medline].
|
| 2.
|
Bachmann, M. F.,
U. Kalinke,
A. Althage,
G. Freer,
C. Burkhart,
H. P. Roost,
M. Aguet,
H. Hengartner, and R. M. Zinkernagel.
1997.
The role of antibody concentration and avidity in antiviral protection.
Science
276:2024-2028[Abstract/Free Full Text].
|
| 3.
|
Camargo, E. P.
1964.
Growth and differentiation in Trypanosoma cruzi. Origin of metacyclic trypanosomes in liquid media.
Rev. Inst. Med. Trop.
6:93-100.
|
| 4.
|
Camargo, M. E.,
S. M. da Silva,
P. G. Leser, and C. H. Granato.
1991.
Avidez de anticorpos IgG especificos como marcadores de infecçao primária recente pelo Toxoplasma gondii.
Rev. Inst. Med. Trop.
33:213-218.
|
| 5.
|
Cozon, G. J.,
J. Ferrandiz,
H. Nebbi,
M. Wallon, and F. Peyron.
1988.
Estimation of the avidity of immunoglobulin G for routine diagnosis of chronic Toxoplasma gondii infection in pregnant women.
Eur. J. Clin. Microbiol. Infect. Dis.
17:32-36.
|
| 6.
|
Davila, H.,
S. Revelli,
H. Moreno,
J. Valenti,
O. Musso,
H. Poli,
J. Morini, and O. Botasso.
1994.
Infection with Trypanosoma cruzi during pregnancy in rats and a decrease in chronic myocardial lesions in their infected offspring.
Am. J. Trop. Med. Hyg.
50:506-511.
|
| 7.
|
Ferreira, M. U.,
E. A. S. Kimura,
J. M. Souza, and A. M. Katzin.
1996.
The isotype composition and avidity of naturally acquired anti-Plasmodium falciparum antibodies: differential patterns in clinically immune Africans and Amazonian patients.
Am. J. Trop. Med. Hyg.
53:315-323.
|
| 8.
|
Hedman, K.,
M. Lampalainen,
M. Söderlund, and L. Hedman.
1993.
Avidity of IgG in serodiagnosis of infectious diseases.
Rev. Med. Microbiol.
4:123-129.
|
| 9.
|
Hedman, K.,
M. I. Lamppalainen,
I. Seppälä, and O. Mäkela.
1989.
Recent primary toxoplasma infection indicated by a low avidity of specific IgG.
J. Infect. Dis.
159:736-740[Medline].
|
| 10.
|
Holliman, R. E.
1994.
Recent developments in the diagnosis of toxoplasmosis.
Serodiagn. Immunother. Infect. Dis.
6:5-16.
|
| 11.
|
Kangro, H. O.,
S. Manzoor, and D. R. Harper.
1991.
Antibody avidity following varicella zoster virus infection.
J. Med. Virol.
33:100-105[Medline].
|
| 12.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 13.
|
Lamppalainen, M.,
P. M. Koskela,
M. Koskiniemiemi,
P. Ammala,
V. Hiilesmaa,
K. Teramo,
K. O. Raivio,
J. S. Remington, and K. Hedman.
1993.
Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of immunoglobulin G.
J. Infect. Dis.
67:691-697.
|
| 14.
|
Lutz, E.,
K. N. Ward, and J. J. Gray.
1994.
Maturation of antibody avidity after primary human cytomegalovirus infection is delayed in immunosuppressed solid organ transplant patients.
J. Med. Virol.
44:317-322[Medline].
|
| 15.
|
Marcolino, P. T.,
D. A. O. Silva,
P. G. Lesser,
M. E. Camargo, and J. R. Mineo.
2000.
Molecular markers in acute and chronic phases of human toxoplasmosis: determination of immunoglobulin G avidity by Western blotting.
Clin. Diagn. Lab. Immunol.
7:384-389[Abstract/Free Full Text].
|
| 16.
|
Mauracher, C. A.,
L. A. Mitchel, and A. J. Tingle.
1992.
Differential IgG avidity to rubella virus structural proteins.
J. Med. Virol.
36:202-208[Medline].
|
| 17.
|
Motran, C. C.,
F. M. Cerbán,
H. Rivarola, and E. Vottero de Cima.
1999.
Characterization of autoantibodies generated in mice by immunization with the C-terminal region of Trypanosoma cruzi ribosomal P1 and P2 proteins.
Clin. Immunol.
91:17-24[Medline].
|
| 18.
|
Newkirk, M. M.,
M. J. Fournier, and J. Shiroky.
1995.
Rheumatoid factor avidity in patients with rheumatoid arthritis: identification of pathogenic RFs which correlate with disease parameters and with the gal(0) glycoform of IgG.
J. Clin. Immunol.
15:250-257[CrossRef][Medline].
|
| 19.
|
Nossal, G. J. V.
1992.
The molecular and cellular basis of affinity maturation in the antibody response.
Cell
68:1-2[CrossRef][Medline].
|
| 20.
|
Paul, M.
1999.
Immunoglobulin G avidity in diagnosis of toxoplasmic lymphadenopathy and ocular toxoplasmosis.
Clin. Diagn. Lab. Immunol.
6:514-518[Abstract/Free Full Text].
|
| 21.
|
Pullen, G. R.,
M. G. Fitzgerald, and C. S. Hosking.
1986.
Antibody avidity determination by ELISA using thiocyanate elution.
J. Immunol. Methods
86:83-87[CrossRef][Medline].
|
| 22.
|
Revelli, S. S.,
N. Amerio,
H. S. Moreno,
J. L. Valenti,
H. Balbarrey, and J. C. Morini.
1980.
Enfermedad de Chagas crónica en la rata. Características serológicas electrocardiográficas e histopatológicas.
Medicina (Buenos Aires)
40:69-76.
|
| 23.
|
Schlesinger, Y., and D. M. Granoff.
1992.
Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines.
JAMA
267:1489-1494[Abstract].
|
| 24.
|
Sennhauser, F. H.,
R. A. Macdonald,
D. M. Roberton, and C. S. Hosking.
1989.
Comparison of concentration and avidity of specific antibodies to E. coli in breast milk and serum.
Immunology
66:394-397[Medline].
|
| 25.
|
Thomas, H. I.,
S. Wilson,
C. M. O'Toole,
C. M. Lister,
A. M. Saeed,
R. P. Watkins, and P. Morgan-Capner.
1996.
Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
Clin. Exp. Immunol.
103:185-191[CrossRef][Medline].
|
Clinical and Diagnostic Laboratory Immunology, July 2001, p. 802-805, Vol. 8, No. 4
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.4.802-805.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.